We advised the underwriters on the equity offering

Davis Polk advised the representative of the underwriters in connection with the $75 million SEC-registered offering of 15,000,000 common shares of InflaRx N.V. and warrants to purchase 15,000,000 common shares of InflaRx N.V. The common shares are listed on the Nasdaq Global Market under the symbol “IFRX.”

Based in Jena, Germany, InflaRx develops new first-in-class therapeutics targeting acute and chronic inflammation. Its primary focus is on the development of monoclonal antibodies that target activation products of the complement system for application in life-threatening inflammatory diseases.

The Davis Polk corporate team included partners Yasin Keshvargar and Derek Walters and associate David Li.  The tax team included partner Mario J. Verdolini and associate Eitan Ulmer. The intellectual property and technology transactions team included partner David R. Bauer and associate Hilary Smith. All members of the Davis Polk team are based in the New York office. 

Copy link to share post